BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025..

波士顿，2025年4月2日（环球新闻社）——Aura Biosciences公司（纳斯达克股票代码：AURA），一家致力于开发保留器官功能的实体瘤精准疗法的临床阶段生物技术公司，今天宣布任命武田全球肿瘤业务部总裁特蕾莎·比泰利为公司董事会成员，自2025年3月31日起生效。

“I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.”.

“Aura Biosciences首席执行官伊丽莎白·德·洛斯·皮诺斯表示：“我非常高兴欢迎特蕾莎加入我们的董事会。她是一位经验丰富的领导者，其广泛的运营和商业经验将对我们推进眼科和泌尿肿瘤学的临床管线起到重要作用。”

“I am excited to join Aura’s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical need,” said Ms. Bitetti. “I look forward to collaborating with the Aura team as they continue to grow as an innovative global oncology company and work to fulfill their mission of transforming patients’ lives.”.

“我非常高兴能够加入Aura董事会，因为公司正在努力开发针对高度未满足医疗需求领域的新疗法，”比蒂女士说道。“我期待与Aura团队合作，因为他们将继续成长为一家创新的全球肿瘤学公司，并努力实现改变患者生活的使命。”

Ms. Bitetti is currently the President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Ms. Bitetti leads all aspects of Takeda’s multi-billion-dollar oncology business, with major markets in the US, Europe, and Japan.

比泰蒂女士目前是武田全球肿瘤业务部的总裁，也是武田执行团队的成员，她负责监督针对胃肠道、胸部和血液癌症的全球治疗产品组合。在此职位上，比泰蒂女士领导着武田数十亿美元肿瘤业务的各个方面，其主要市场在美国、欧洲和日本。

Before joining Takeda, Ms. Bitetti was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). She held leadership roles of increasing responsibility at BMS, including in infectious diseases and neuroscience. She served as Senior Vice President and Head of U.S.

在加入武田之前，比蒂蒂女士曾担任百时美施贵宝（BMS）全球肿瘤商业化高级副总裁兼负责人。她在BMS担任过多个责任日益增加的领导职位，包括传染病和神经科学领域。她还曾担任美国地区高级副总裁兼负责人。

Oncology, President and General Manager of BMS Canada, and Worldwide Head of BMS Virology. Prior to BMS, Ms. Bitetti was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil’s worldwide pension assets. In addition to her role at Takeda, Ms. Bitetti serves on the Board of Directors for Osmol Therapeutics, which is focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy.

肿瘤学、百时美施贵宝加拿大公司总裁兼总经理，以及百时美施贵宝病毒学全球负责人。在加入百时美施贵宝之前，比蒂女士曾是美孚石油公司资本市场的成员，负责监管美孚全球养老金资产的投资。除了在武田的职务外，比蒂女士还担任Osmol Therapeutics公司的董事会成员，该公司专注于开发预防化疗引起的周围神经病变的治疗方法。

Ms. Bitetti earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College..

比蒂蒂女士在弗吉尼亚大学达顿商学院获得MBA学位，并在韦尔斯利学院获得学士学位。

About Aura Biosciences

关于Aura生物科学公司

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

Aura Biosciences是一家临床阶段的生物技术公司，专注于开发旨在保留器官功能的实体瘤精准疗法。我们的主要候选药物bel-sar（AU-011）目前正处于脉络膜黑色素瘤晚期开发阶段，并在其他眼部肿瘤适应症和膀胱癌的早期开发中。Aura Biosciences总部位于马萨诸塞州波士顿。我们的使命是成长为一家创新的全球肿瘤学公司，积极改变患者的生活。

For more information, visit .

如需更多信息，请访问。

aurabiosciences.com

奥拉生物科技公司.com

. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

请在X（原Twitter）上关注我们 @AuraBiosciences，并在LinkedIn上访问我们。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）及其他联邦证券法所指的前瞻性陈述。任何非历史事实的陈述均可被视为前瞻性陈述。诸如“可能”、“将”、“可能”、“应该”、“预期”、“打算”、“计划”、“预计”、“相信”、“估计”、“预测”、“项目”、“寻求”、“努力”、“潜在”、“继续”等词汇或这些词汇的否定形式或其他类似表达可用于识别前瞻性陈述。

These forward-looking statements include express or implied statements regarding Aura’s future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of bel-sar for the treatment of multiple cancers; statements regarding Aura’s plans and expectations for its ongoing and future clinical trials of bel-sar in multiple oncology indications; statements regarding Aura’s plans to advance its clinical pipeline; statements regarding achieving Aura’s goal to transform patients’ lives; and statements regarding Aura’s expectations for the estimated patient populations and related market opportunities for bel-sar..

这些前瞻性声明包括关于Aura未来预期、计划和前景的明确或隐含声明，包括但不限于关于bel-sar在治疗多种癌症方面的治疗潜力的声明；关于Aura对其在多种肿瘤适应症中正在进行和未来临床试验的计划和预期的声明；关于Aura推进其临床管线的计划的声明；关于实现Aura转变患者生活的目标的声明；以及关于Aura对bel-sar预计患者群体及相关市场机会的预期的声明。

The forward-looking statements in this press release are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Aura’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura’s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that early or interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with Aura’s clinical trial designs, even where Aura has obtained agreement with governmental authorities on the design of such trials, such as the Phase 3 special protocol assessment agreement with the U.S.

本新闻稿中的前瞻性陈述既不是承诺也不是保证，投资者不应过度依赖这些前瞻性陈述，因为它们涉及已知和未知的风险、不确定性及其他因素，其中许多因素超出Aura的控制范围，并可能导致实际结果与这些前瞻性陈述中明示或暗示的结果存在重大差异，包括但不限于临床试验内在的不确定性以及正在进行的临床试验数据的可用性和时间安排的不确定性；提交监管审批或政府机构审查的预期时间；Aura的临床前和临床试验结果可能无法预测未来临床试验相关结果的风险；正在进行的临床试验的早期或中期数据可能无法预测已完成临床试验的最终数据的风险；即使Aura已就试验设计（例如与美国达成的第3阶段特殊方案评估协议）获得政府机构的同意，政府机构仍可能不同意Aura的临床试验设计的风险。

Food and Drug Administration; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Aura’s ongoing and planned preclinical activities; and Aura’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials.

食品药品监督管理局；Aura是否将获得进行试验或市场营销产品的监管批准；Aura的现金资源是否足以支付其可预见和不可预见的运营费用及资本支出需求；Aura正在进行和计划的临床前活动；以及Aura启动、招募、进行或完成正在进行和计划的临床试验的能力。

These risks, uncertainties and other factors include those risks and uncertainties described under the heading “Risk Factors” in Aura’s most recent Annual Report on Form 10-K and Q.

这些风险、不确定性和其他因素包括Aura最近的Form 10-K和Q年度报告中“风险因素”标题下描述的风险和不确定性。

www.sec.gov

www.sec.gov

. Except as required by law, Aura disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Aura’s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements..

除非法律要求，Aura否认有任何意图或责任更新或修改本新闻稿中包含的任何前瞻性声明，无论是在新信息、未来发展或其他情况下。这些前瞻性声明基于Aura的当前预期，仅截至本日期有效，且不对任何此类前瞻性声明的准确性作出明示或暗示的陈述或保证。

Investor and Media Contact:

投资者和媒体联系人：

Alex Dasalla

亚历克斯·达萨拉

Head of Investor Relations and Corporate Communications

投资者关系和企业传播主管

IR@aurabiosciences.com

IR@aurabiosciences.com